Recent News

• 03.31.2025 - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
• 03.27.2025 - Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
• 03.17.2025 - Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.11.2025 - Robert LeBoyer

Recent Filings

• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities